全基因组荟萃分析验证S1PR1在微管靶向药物诱导的周围神经病变中的作用
该药物基因组学研究对两项接受微管靶向药物治疗的临床试验(CALGB 40502和CALGB 40101)进行全基因组关联分析荟萃分析,发现S1PR1下游增强子区的新单核苷酸多态性与≥2级周围神经病变风险显著相关,并在人诱导多能干细胞来源的感觉神经元中验证抑制S1PR1可部分减轻紫杉醇诱导的神经突损伤。
要点
- S1PR1增强子区变异与MTA诱导的≥2级周围神经病变风险相关。
- 抑制S1PR1可部分保护紫杉醇诱导的人感觉神经元神经突损伤。
- S1PR1可能成为预防或治疗MTA诱导神经病变的靶点。
核心结论
- S1PR1下游增强子区的单核苷酸多态性与微管靶向药物诱导的≥2级感觉周围神经病变风险相关。
研究设计与样本
- 对CALGB 40502(欧洲裔,n=469)和CALGB 40101(欧洲裔,n=855)两项临床试验的全基因组关联分析进行荟萃分析。
- 使用Cox回归模型,以累积剂量至首次发生≥2级周围神经病变为结局。
主要发现
- S1PR1下游增强子区的新单核苷酸多态性(如rs74497159)与≥2级周围神经病变风险的关联最为显著。
- rs74497159每等位基因对数风险比:CALGB 40101为0.591(95%CI 0.254-0.928),CALGB 40502为0.693(95%CI 0.334-1.053),荟萃分析P=3.62×10⁻⁷。
- 计算机功能分析识别出该基因组区域内多个调控元件和S1PR1的潜在增强子活性。
- 在诱导多能干细胞来源的人感觉神经元中抑制S1PR1功能,可部分保护免受紫杉醇诱导的神经突损伤。
临床怎么用
- 这些药物遗传学发现支持进一步开展临床评估,以S1PR1为靶点预防和/或治疗微管靶向药物诱导的神经病变。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Microtubule targeting agents (MTAs) are anticancer therapies commonly prescribed for breast cancer and other solid tumors. Sensory peripheral neuropathy (PN) is the major dose-limiting toxicity for MTAs and can limit clinical efficacy. The current pharmacogenomic study aimed to identify genetic variations that explain patient susceptibility and drive mechanisms underlying development of MTA-induced PN. A meta-analysis of genomewide association studies (GWAS) from two clinical cohorts treated with MTAs (Cancer and Leukemia Group B (CALGB) 40502 and CALGB 40101) was conducted using a Cox regression model with cumulative dose to first instance of grade 2 or higher PN. Summary statistics from a GWAS of European subjects (n = 469) in CALGB 40502 that estimated cause-specific risk of PN were meta-analyzed with those from a previously published GWAS of European ancestry (n = 855) from CALGB 40101 that estimated the risk of PN. Novel single nucleotide polymorphisms in an enhancer region downstream of sphingosine-1-phosphate receptor 1 (S1PR1 encoding S1PR1 ; e.g., rs74497159, βCALGB 40101 per allele log hazard ratio (95% confidence interval (CI)) = 0.591 (0.254-0.928), βCALGB 40502 per allele log hazard ratio (95% CI) = 0.693 (0.334-1.053); PMETA = 3.62 × 10-7 ) were the most highly ranked associations based on P values with risk of developing grade 2 and higher PN. In silico functional analysis identified multiple regulatory elements and potential enhancer activity for S1PR1 within this genomic region. Inhibition of S1PR1 function in induced pluripotent stem cell-derived human sensory neurons shows partial protection against paclitaxel-induced neurite damage. These pharmacogenetic findings further support ongoing clinical evaluations to target S1PR1 as a therapeutic strategy for prevention and/or treatment of MTA-induced neuropathy.
引用
- Chua KC, Xiong C, Ho C, et al. Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy. Clin Pharmacol Ther. 2020. PMID: 32562552. doi:10.1002/cpt.1958
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。